ABBOTT INDIA LIMITED
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-14
- Lead Sponsor
- Abbott
- Registration Number
- NCT00650026
Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: adalimumabBiological: placebo
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Abbott
- Target Recruit Count
- 47
- Registration Number
- NCT00647920
Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: adalimumabBiological: placebo
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Abbott
- Target Recruit Count
- 226
- Registration Number
- NCT00649922
Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Abbott
- Registration Number
- NCT00650390
Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Abbott
- Registration Number
- NCT00649545
Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2011-04-11
- Lead Sponsor
- Abbott
- Target Recruit Count
- 420
- Registration Number
- NCT00647270
Adalimumab in Adult Japanese Subjects With Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: adalimumab
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Abbott
- Target Recruit Count
- 147
- Registration Number
- NCT00647400
- Locations
- 🇯🇵
Site Ref # / Investigator 5495, Hiroshima-city, Japan
🇯🇵Site Ref # / Investigator 5491, Bunkyo-ku, Japan
🇯🇵Site Ref # / Investigator 5429, Chiyoda-ku, Japan
A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: adalimumabBiological: placebo
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 352
- Registration Number
- NCT00647491
Paricalcitol Injection Phase II Trial
- First Posted Date
- 2008-03-31
- Last Posted Date
- 2008-03-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 25
- Registration Number
- NCT00646932
Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Abbott
- Target Recruit Count
- 32
- Registration Number
- NCT00645892
© Copyright 2025. All Rights Reserved by MedPath